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Background: Fatigue, which is commonly observed in Parkinson’s disease (PD), can greatly reduce quality of life
and is difficult to treat. We here aimed to investigate the prevalence and characteristics of fatigue among PD
patients and to explore an effective strategy to treat PD fatigue.
Method: This was an observational cross-sectional study conducted in northeastern China. We examined fatigue in
222 PD patients from northeastern China using the Parkinson Fatigue Scale-16 (PFS-16). The disease severity,
depression, sleep and cognitive functioning were assessed with the Hoehn & Yahr staging (H-Y stage), Unified
Parkinson’s Disease Rating Scale (UPDRS), Hamilton Depression Scale (HAMD), Parkinson’s Disease Sleep Scale (PDSS)
and Montreal Cognitive Assessment (MoCA) by interview.
Results: The frequency of fatigue in PD patients was 59.46 %. Fatigued patients had longer disease durations and
greater disease severity than nonfatigued patients. Additionally, fatigued PD patients scored significantly higher for
all motor symptoms, except for tremor, and had more serious depressive symptoms and sleep disturbances than
nonfatigued PD patients did. The sleep disturbance severity was an independent factor for fatigue. Furthermore,
43.04 % of fatigued patients taking dopaminergic drugs had fatigue remission. Depression severity was identified as
an independent factor for dopaminergic drug non-responsive fatigue.
Conclusions: PD patients with severe sleep disturbances tend to suffer from fatigue. Levodopa improved fatigue
only in PD patients with mild depression or no depression, implying that dopaminergic medication is required, but
not sufficient, for fatigue suppression in PD patients with moderate or severe depression. Thus, restoring
serotonergic neurotransmission as a combination therapy may offer a better strategy for the treatment of fatigue in
these patients.
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Fatigue is one of the most common non-motor symptoms
in Parkinson disease (PD). Currently, there is no univer-
sally accepted definition of fatigue in PD. PD patients
complaining about fatigue describe it as a sensation of
tiredness, lack of energy, or exhaustion. These states are
experienced as abnormally severe. It is often unpredictable
in its onset and duration, often attributable to activity
levels [1]. According to a recent study in PD, fatigue is* Correspondence: grace_shenyang@163.com
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confirmed as the most disabling symptom by 15–33 % of
PD patients [3, 4]. Despite its high prevalence and nega-
tive impact on life quality, fatigue in PD remains an
under-recognized problem in routine clinical practice [5].
Most of the published investigations have focused on
prevalence and clinical characteristics of PD related
fatigue, and found the close relationship between fatigue,
sleep disturbance, depression and anxiety [6–8]. How-
ever few of them explored the prevalence and profiles of
dopaminergic-responsive fatigue in fatigued PD patients
on dopaminergic treatment. Previous studies have shown
that dopamine is involved in the development of exercise-istributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
t to the original author(s) and the source, provide a link to the Creative
re made. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fu et al. Translational Neurodegeneration  (2016) 5:9 Page 2 of 7induced fatigue [9, 10]. Decreased dopamine levels were
detected in the brain using a rat model of exercise-induced
fatigue [11], indicating that the shortage of dopamine con-
tributed to the occurrence of fatigue. This is consistent with
the ELLDOPA Trial [12], which noted improved fatigue
with levodopa treatment, even though the benefit was min-
imal. However, a recent meta-analysis of the intervention
for fatigue in PD concluded [13] that currently there is
insufficient evidence to support the effective treatment of
fatigue in PD with any drug. Clinically, we do have some
patients whose fatigue can be relieved with levodopa treat-
ment, in our personal experience. Therefore, in the present
study, we specifically examined fatigue and fatigue-related
clinical features in patients with PD to determine the
clinical characteristics of fatigue in PD patients. More im-
portantly, we aimed to clarify the profile of dopaminergic-
responsive fatigue and its associated factors.
Methods
Subjects and demographic data
This was an observational cross-sectional study. Two hun-
dred and twenty-two PD patients, diagnosed according to
the UK PD Brain Bank criteria [14], were recruited
between December 2012 and April 2014 from the out-
patient Department of Neurology of the First Affiliated
Hospital of China Medical University (Shenyang, China).
Patients with other forms of parkinsonism were excluded.
Patients with dementia or fatigue related to a disease other
than PD were excluded (e.g., peripheral circulatory disor-
ders, such as ischemic heart disease and left ventricular
failure, or acute and chronic inflammatory demyelinating
polyneuropathies, such as Guillain-Barre syndrome). All
patients enrolled in the study gave written informed con-
sent. The Ethics Review Board of First Affiliated Hospital
of China Medical University (Shenyang, China) approved
the protocol of the study. Demographic data were col-
lected for all PD patients. The total amount of dopamin-
ergic medication was expressed as the levodopa equivalent
daily dosage (LEDD), which was determined using
methods previously reported in a systematic review of
LEDD [15].
Assessments
Disease severity was evaluated during the on phase using
the Unified Parkinson’s Disease Rating Scale (UPDRS) and
Hoehn & Yahr staging (H-Y stage) [16]. As previously
described [17], the following sub-scores obtained from
specific items of UPDRS III were calculated as following:
tremor (items 20 and 21), rigidity (item 22), bradykinesia
(items 23–26 and 31) and posture/gait (items 27–30).
Fatigue was assessed using the Parkinson Fatigue Scale-
16 (PFS-16). The PFS-16 is a 16-item self-report scale that
is specifically designed to assess the physical aspects of
fatigue in PD patients [1]. The item response optionsrange from 1 (“strongly disagree”) to 5 (“strongly agree”).
The total PFS-16 score ranges from 1 to 5 and is obtained
by dividing the sum of all item scores by 16 [18]. A cut-off
score of 3.3 was used to indicate the presence of fatigue
[1]. Subjects with a PFS-16 score <3.3 were classified as
nonfatigued, and those scoring ≥3.3 were classified as
fatigued.
The Montreal Cognitive Assessment (MoCA) Beijing ver-
sion was used to evaluate cognitive functioning. Because
depression and sleep disturbances have been reported to
affect fatigue, we revised our study protocol during the
study. The 17-item Hamilton Depression Scale [19]
(HAMD) and Parkinson’s Disease Sleep Scale (PDSS) [20]
were administered to 177 of the 222 patients to assess de-
pression and sleep disturbance, respectively. In the 17-item
HAMD, a higher score indicates severe depression, and
depression was classified as follows: no depression (0–7);
mild depression (8–16); moderate depression (17–23); and
severe depression (≥24) [21]. The range of PDSS score was
0–150, and a lower score indicated a higher number of
sleep disturbances.
Statistical analysis
All continuous data are presented as the mean ± standard
deviation (SD). Categorical variables were compared with
chi-square tests; the Mann-Whitney U test was used for
continuous variables. Correlations were assessed using
Spearman rank order correlation coefficients. The odds
ratios were calculated using logistic regression and chi-
square tests. All data analyses were performed using SPSS
software. A value of P < 0.05 was considered statistically
significant.
Results
Comparison of demography and clinical profiles between
the fatigued and nonfatigued groups
According to the suggested cut-off score for the PFS-16
(≥3.3), fatigue was present in 132 (59.46 %) patients.
Comparisons of the demographic and clinical character-
istics between the fatigued and nonfatigued groups are
listed in Table 1. The mean disease duration in the nonfa-
tigued group was significantly shorter than that in the
fatigued group (3.75 ± 3.26 years vs. 4.61 ± 2.99 years, p =
0.046). There were no significant differences between the
two groups in other clinical characteristics, including sex,
age, onset age and education.
Disease severity, as determined by H-Y stage and the
total UPDRS score and all subscales, was more serious in
the fatigued group than in the nonfatigued group (Table 1).
Further analysis of the individual motor symptoms re-
vealed that except for tremor, most motor symptoms, in-
cluding rigidity, bradykinesia and posture/gait, were more
serious (higher scores) in the fatigued group than in the
nonfatigued group (Table 1). Similarly, the fatigued group
Table 1 Demographic and clinical characteristics of fatigued
vs.nonfatigued subjects








Age, y 61.63 ± 9.49 62.50 ± 10.21 0.524
Onset age, y
(n= 222)




3.75 ± 3.26 4.61 ± 2.99 0.046*
Education, y
(n= 222)




211.19 ± 263.18 280.24 ± 304.04 0.081
H-Y stage
(n= 222)
1.73 ± 0.78 2.00 ± 0.76 0.009*
UPDRS total
score (n= 222)
39.43 ± 20.26 52.39 ± 20.19 <0.001*
UPDRS part I
(n= 222)
2.93 ± 1.93 4.19 ± 2.26 <0.001*
UPDRS part II
(n= 222)
9.88 ± 4.80 12.57 ± 5.72 <0.001*
UPDRS part III
(n= 222)








12.30 ± 7.98 15.9 ± 7.35 0.001*
Rigidity
(UPDRS item 22)




3.36 ± 3.26 3.78 ± 3.88 0.391
UPDRS IV
(n= 222)
0.86 ± 1.65 1.70 ± 2.57 0.007*
MoCA
(n= 222)
22.87 ± 4.59 21.85 ± 4.27 0.066
HAMD
(n= 177)
7.26 ± 5.47 9.32 ± 5.17 0.006*
PDSS
(n= 177)
119.10 ± 23.65 98.82 ± 25.74 <0.001*
Data are expressed as numbers, with percentages in parentheses, or as mean
± SD. *Significant difference. H-Y stage Hoehn & Yahr staging, LEDD levodopa
equivalent daily dosage, UPDRS Unified Parkinson’ Disease Rating Scale, MoCA
Montreal Cognitive Assessment, HAMD Hamilton Depression Scale score, PDSS
Parkinson’s Disease Sleep Scale
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and sleep disturbance than the nonfatigued group had
(Table 1).
The LEDD and MoCA scores tended to be higher in
the fatigued group than in the nonfatigued group, but
this was not significant.Independent risk factors related to fatigue
As shown in Table 2, the univariate logistic regression
revealed that longer disease duration, a greater disease
severity (H-Y stage, total UPDRS score and all subscales),
depression and sleep disturbances were associated with
fatigue (p< 0.05). Other clinical variables, including gen-
der, age onset age, education, LEDD and MoCA score
were not significantly associated with fatigue.
We further explored the independent risk factors of
fatigue in PD patients using multivariate logistic regres-
sion. Only sleep disturbance (odds ratio = 0.974, 95%CI
0.959–0.989, P = 0.001) remained an independent risk fac-
tor for fatigue (Table 2). Disease duration, disease severity
(H-Y stage, total UPDRS score and all subscales) and
depression were not associated with fatigue (Table 2).
Comparison of clinical variables between the
dopaminergic responsive fatigue and dopaminergic
non-responsive fatigue groups
To further explore the clinical profiles of dopaminergic
drug responsive fatigue, we examined the data of 79
patients in the fatigued group with complaints of fatigue
and who were treated with dopaminergic drugs. We
defined the fatigue amelioration rate between 0 % and
100 %, and assigned fatigue remission rate into 4 level
(level 0: no remission, remission rate <25 %; level 1: mild
remission, remission rate between 25 % and 50 %; level 2:
moderate remission, remission rate between 50 % and
75 %; level 3: obvious remission, remission rate over 75 %)
with a lower level indicating less responsiveness to dopa-
minergic medication. According to their response to
dopaminergic drugs the 79 patients were assigned to
either the dopaminergic drug responsive fatigued (DDRF)
group (fatigue amelioration rate > level 0) or the dopamin-
ergic drug non-responsive fatigued (DDNRF) group (fa-
tigue amelioration rate = level 0).
The demographic and clinical profiles were compared
between the DDRF and DDRNF groups; the results of
these comparisons are shown in Table 3. There were 34
(43.04 %) patients in the DDRF group and 45 (56.96 %)
patients in the DDNRF group. Onset age was significantly
higher in the DDNRF group than in the DDRF group, and
significantly more severe depression was found in the
DDNRF group. There were no significant differences be-
tween the two groups in age, sex, disease duration, educa-
tion, disease severity (H-Y stage, UPDRS total score and
all subscores), individual motor symptoms, sleep disturb-
ance or cognitive functioning (Table 3).
Depression severity is an independent risk factor for
dopaminergic drug non-responsive fatigue
As shown in Table 4, the Spearman rank order correlation
coefficients revealed significant correlations between fa-
tigue remission rate and age, onset age, and depression
Table 2 Logistic regression modal of the association between






















































































Figures in parentheses indicate 95 % confidence intervals. *Significant
difference. H-Y stage Hoehn & Yahr staging, LEDD levodopa equivalent daily
dosage, UPDRS Unified Parkinson’ Disease Rating Scale, MoCA Montreal
Cognitive Assessment, HAMD Hamilton Depression Scale score, PDSS
Parkinson’s Disease Sleep Scale
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disease severity (H-Y stage, UPDRS total score and all sub-
scales) and cognitive functioning were not associated with
the fatigue remission rate.
To identify independent factors influencing dopamin-
ergic responsive fatigue, variables significantly associated
with fatigue remission rate in the bivariate correlation
analyses (Table 4) were entered as independent variables
into a logistic regression model. Only depression severity
(odds ratio = 1.182, 95%CI 1.044–1.338, P = 0.008) was
identified as an independent risk factor for dopaminergic
drug non-responsive fatigue.Discussion
In the present study, fatigue problems were found in
more than half of the PD patients (59.46 %) in north-
eastern China, which is consistent with previous reports
[3, 22–24]. Moreover, fatigue appeared to be related with
prolonged disease duration, increased disease severity,
enhanced depressive symptoms, serious sleep disturb-
ance, and the development of motor symptoms, except
tremors. A univariate logistic regression analysis demon-
strated that fatigue was significantly associated with sev-
eral clinical characteristics of PD patients. Among the
variables examined, only sleep disturbance was identified
as an independent risk factor for fatigue. In addition, fa-
tigue remission was found in 43.04 % of fatigued patients
taking dopaminergic drugs. The development of DDNRF
was associated with an older age and depressive symp-
toms, and depression severity was an independent risk
factor for dopaminergic drug non-responsive fatigue.
Our findings provide basic evidence for understanding
the clinical significance of the non-motor symptom of
fatigue in PD.Sleep disturbance is an independent risk factor for
fatigue in PD patients
Sleep is necessary for the maintenance of mammalian
homeostasis. Additionally, sleep is one of the most cru-
cial determinants of fatigue severity [25]. In the general
population, high-quality sleep is associated with less fa-
tigue [26, 27]. Sleep disturbance has been associated
with fatigue in several disorders, including cancer [28],
multiple sclerosis [29] and traumatic brain injury [30].
In addition, it was reported that dissatisfaction with
sleep, and not sleep itself, was associated with fatigue in
psychotic patients [31].
Although the mechanisms of sleep abnormalities and
fatigue have not yet been clarified, increased inflamma-
tory cytokine release has been associated with poor sleep
conditions and fatigue [32]. Specifically, the production
of interleukin (IL)-1β and tumor necrosis factor (TNF)-α
promotes non-rapid eye movement sleep (NREMS)
under physiological and inflammatory conditions. Dis-
turbed NREMS is associated with abnormal cyclic alter-
nating pattern (CAP) rates and electroencephalogram
arousals, and it is correlated with fatigue and sleepiness
[33]. IL-1β and TNF-α alter neuronal excitability and in-
duce symptoms associated with sleep loss by binding to
their neural receptors, which subsequently regulate neu-
rotransmitters or neuromodulators [34]. Moreover, the
neurotransmitter serotonin governs sleep-wake behavior
[35], and a reduction of serotonin transporters was
found in subjects with fatigue syndrome [36]. These
findings suggest that serotoninergic functions may play
pivotal roles in controlling sleep and fatigue.
Table 4 Correlations between fatigue remission rate and clinical





Age, y −0.223 0.049*
Onset age, y −0.250 0.026*
Duration of disease 0.123 0.282
Education, y 0.010 0.929
LEDD 0.003 0.976
PFS total score −0.155 0.173
H-Y stage 0.089 0.436
UPDRS total score 0.033 0.772
UPDRS part I 0.053 0.645
UPDRS part II −0.029 0.798
UPDRS part III 0.074 0.515




*Significant difference. H-Y stage Hoehn & Yahr staging, LEDD levodopa
equivalent daily dosage, UPDRS Unified Parkinson’ Disease Rating Scale, MoCA
Montreal Cognitive Assessment, HAMD Hamilton Depression Scale score, PDSS
Parkinson’s Disease Sleep Scale
Table 3 Comparison between dopaminergic drug responsive
fatigue (DDRF) and dopaminergic drug non-responsive fatigue
(DDNRF)
Variable DDRF DDNRF p
Male (n= 79) 13 (38.24 %) 24 (53.33 %) 0.354
Age, y (n= 79) 59.59 ± 8.89 63.64 ± 11.80 0.074
Onset age, y (n= 79) 54.24 ± 8.95 58.82 ± 11.93 0.040*
Duration of disease
(n= 79)
5.35 ± 3.02 4.82 ± 3.24 0.276
Education, y (n= 79) 10.03 ± 2.93 9.36 ± 4.23 0.681
LEDD (mg/day)
(n= 79)
473.38 ± 281.42 438.26 ± 271.25 0.804
H-Ystage (n= 79) 2.15 ± 0.82 2.04 ± 0.74 0.526
UPDRS total (n= 79) 55.94 ± 21.46 52.91 ± 20.22 0.674
UPDRS I (n= 79) 4.06 ± 2.15 3.87 ± 2.61 0.506
UPDRS II (n= 79) 13.00 ± 5.65 13.59 ± 6.36 0.67
UPDRS III (n= 79) 36.76 ± 15.50 33.63 ± 14.67 0.362
Gait (n= 79) 5.12 ± 3.15 5.26 ± 3.41 0.843
Tremor (n= 79) 4.32 ± 4.20 320 ± 3.89 0.19
Rigidity (n= 79) 7.56 ± 4.59 6.20 ± 4.19 0.198
Bradykinesia (n= 79) 16.94 ± 7.50 16.38 ± 7.47 0.741
UPDRS IV (n= 79) 2.11 ± 2.77 1.82 ± 2.70 0.541










MoCA (n= 79) 22.47 ± 4.14 21.42 ± 4.59 0.353
Data are expressed as numbers, with percentages in parentheses, or as mean
± SD. *Significant difference. DDRF dopaminergic drug responsive fatigue,
DDNRF dopaminergic drug non-responsive fatigueH-Y stage: Hoehn & Yahr
staging, LEDD levodopa equivalent daily dosage, UPDRS Unified Parkinson’
Disease Rating Scale, MoCA Montreal Cognitive Assessment, HAMD Hamilton
Depression Scale score, PDSS Parkinson’s Disease Sleep Scale
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mary neuropsychiatric manifestations of PD, and they are
related to patient quality of life [37, 38]. In this study, a
logistic regression analysis revealed that sleep disturbance
is the only independent factor for fatigue in PD patients,
which is in accordance with the findings of a previous
study [6]. Emerging lines of evidence indicate that sleep
disorder treatment is effective for improving fatigue in
patients with multiple sclerosis [39, 40]. Similarly, the
management of sleep loss may provide a valuable ap-
proach for improving fatigue in PD patients. It has been
proposed that fatigue stems at least in part from disturbed
cytokine production in diseases such as PD [41]. Indeed,
elevated secretion of IL-1β and TNF-α have been detected
in the cerebrospinal fluid (CSF) of PD patients with sleep
problems [42]. The circulating level of IL-1β is also in-
creased in PD patients with fatigue [43]. Pavese et al. indi-
cated that in addition to increased inflammatory cytokine
production, fatigue in PD patients might result fromserotonergic (5-hydroxytryptamine, 5-HT) dysfunction
in the basal ganglia and limbic circuitry [44]. Consid-
ering the crucial roles that cytokine release and serotoner-
gic functioning play in regulating sleep and fatigue, we
hypothesize that sleep disturbance and fatigue may share
a similar mechanism in the pathogenesis of PD, with
abnormal cytokine release and serotonergic dysfunction
being the primary components of this mechanism. Future
studies should explore the molecular mechanisms in-
volved in this process.
Dopamine imbalance is associated with fatigue in PD
patients
Another important finding of the current study was that
dopaminergic medication improved fatigue in 43.04 % of
PD patients with fatigue problems, whereas more than
half of the fatigued patients were not responsive to
dopaminergic medication. This result is consistent with
ELLDOPA study [45], which showed that levodopa/car-
bidopa is effective in reducing the progression of fatigue
in drug naïve PD patients [12]. Moreover, the study of
ADAGIO [46] also showed that rasagiline was associated
with significantly less progression of fatigue compared
with placebo over a 9-month period in drug naïve patients
with PD [47]. Both carbidopa/levodopa and rasagiline are
dopaminergic drugs, which increase the extracellular
levels of dopamine. Thus, we infer dopamine dysfunction
Fu et al. Translational Neurodegeneration  (2016) 5:9 Page 6 of 7may involve in the pathogenesis of fatigue in PD. The ef-
fects we observed might be due to enhanced dopamin-
ergic neurotransmission, indicating the therapeutic value
of dopaminergic treatment for fatigue relief in PD. How-
ever, according to the univariate logistic regression and
correlation analysis performed in our study, there are no
significant associations among fatigue, fatigue severity,
remission rate, and dopaminergic medication dosage be-
cause a no dose-effect correlation was detected between
levodopa and fatigue. Hence, levodopa may play a role in
the mechanism underlying the development of fatigue,
which is consistent with other current results. The dopa-
mine imbalance hypothesis of fatigue was recently
presented in multiple sclerosis and other neurological
disorders [48]. Thus, restoring dopamine levels in the
CNS by means of dopaminergic medication, such as
levodopa, might be an essential strategy for the treat-
ment of fatigue in PD.
Depression is an independent risk factor for
dopaminergic drug non-responsive fatigue
Depression is another prominent non-motor symptom in
PD [49]. Fatigue in PD is often associated with depression,
using a logistic regression model, we further demonstrated
that depression was the only independent factor for the
efficacy of dopaminergic medication in treating fatigue in
PD patients, which might imply crosstalk between depres-
sion, fatigue and dopamine insufficiency.
Pavese et al. found that compared with patients without
fatigue, PD patients with fatigue showed greatly reduced
serotonin transporter binding in the basal ganglia and lim-
bic circuitry, as well as a significant reduction in dopamine
uptake in the caudate and insula [44]. These results dem-
onstrate that even though a dysfunctional serotonergic
pathway plays a predominant role in fatigue, reduced
dopaminergic functioning also contributes to the inci-
dence of fatigue [44]. Hence, both dopaminergic and sero-
tonergic pathways contribute to fatigue in PD patients.
Interestingly, other studies have indicated that excessive
5-HT also induced fatigue. Indeed, increased 5-HT and
decreased dopamine concentrations were detected in the
brain in a rat model of exercise-induced fatigue [50].
These findings imply that the level of 5-HT may not be a
determinant, and maintaining the balance between seroto-
nergic and dopaminergic function is key for fatigue relief.
Hence, dopamine administration may improve fatigue
only in PD patients who have a functional serotonergic
system with normal 5-HT concentrations and receptor
functioning, which is consistent with our results. In other
words, functional serotonergic pathway is necessary for
dopamine to alleviate fatigue. Therefore, both 5-HT and
dopamine should be considered during the treatment of
PD fatigue. For instance, in the early stage of PD, a supple-
ment of only 5-HT without levodopa medication may beinsufficient for relieving fatigue, as levodopa is usually not
prescribed early in PD due to the absence of obvious motor
symptoms. Similarly, when fatigue is present with no obvi-
ous depression, a combined administration of levodopa
with 5-HT, but not levodopa alone, may provide greater
relief from fatigue. Thus, we hypothesize that dopaminergic
medication is required, but not sufficient, for fatigue
suppression in fatigued PD patients with moderate depres-
sion, and such treatment can restore serotonergic neuro-
transmission and serve as a combination therapy. This may
offer an ideal strategy for the treatment of fatigue in PD
patients.
Conclusions
In the present study, we found that fatigue is common
in PD patients. PD patients with severe sleep distur-
bances tend to suffer from fatigue. Levodopa improved
fatigue only in PD patients with mild depression or no
depression, restoring serotonergic neurotransmission as
a combination therapy may offer a better strategy for the
treatment of fatigue in these patients.
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